Parabilis Medicines, Inc. PBLS
27.69 USD -1.96 (-6.61%)
At closeNov 12, 2026, 4:26 PM EST
27.69 0.00 0.00%
After hours · Nov 12, 4:26 PM ET
27.47 Day range 29.88
22.66 52-week range 42.49
- YTD
- -12.37%
- 1 year
- -12.37%
News
benzinga.com Parabilis Medicines Q3 EPS $(0.36), Inline, Sales $2.114M Beat $375.000K Estimate Parabilis Medicines (NASDAQ:PBLS) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 98.34 percent increase over losses of $(21.66) per share from the…
globenewswire.com Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in…
benzinga.com Canaccord Genuity Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $39 Canaccord Genuity analyst John Newman initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $39.
globenewswire.com Parabilis Medicines to Participate in Upcoming November Investor Conferences CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with…
seekingalpha.com Parabilis Medicines: Bullish On Zolucatetide's Broad Oncology Potential Zolucatetide gives PBLS potential in desmoid tumors, but it also has other Wnt-driven indications that could grow its TAM over time. PBLS's PEDESTAL trial is now a clearer R&D path, as long as early…
seekingalpha.com Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
marketbeat.com Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027 Parabilis Medicines NASDAQ: PBLS presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology…
globenewswire.com Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with…
benzinga.com HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40 HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.
seekingalpha.com Parabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For Free Parabilis Medicines, Inc. is rated a speculative Buy due to its innovative peptide platform and strong rare-disease oncology pipeline. Lead asset zolucatetide (zolu) shows robust early efficacy in…
benzinga.com Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.
benzinga.com Parabilis Medicines To Present Updated Clinical Data For Zolucatetide In Patients With Desmoid Tumors At ESMO Congress 2026 Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid…
globenewswire.com Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026 Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid…
benzinga.com Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trial New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumorsZolucatetide directly inhibits β-catenin:TCF,…
globenewswire.com Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors
defenseworld.net Parabilis Medicines (NASDAQ:PBLS) Shares Gap Up – Here’s What Happened Parabilis Medicines, Inc. (NASDAQ: PBLS - Get Free Report)'s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $31.20, but opened at $32.84. Parabilis Medicines…
benzinga.com Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
seekingalpha.com Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with…
globenewswire.com Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D. CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with…
seekingalpha.com Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway…
benzinga.com Parabilis Medicines Q2 EPS $(2.32) Misses $(0.08) Estimate, Sales $148.000K Miss $25.000M Estimate Parabilis Medicines (NASDAQ:PBLS) reported quarterly losses of $(2.32) per share which missed the analyst consensus estimate of $(0.08) by 2800 percent. This is a 89.59 percent increase over losses…
globenewswire.com Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors
247wallst.com Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday.…- benzinga.com Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40 Leerink Partners analyst Andrew Berens initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Outperform rating and announces Price Target of $40.
benzinga.com This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top stocks. See full analyst rating changes & buy/sell recommendations for PBLS stock on Benzinga.- benzinga.com B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45 B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.
fool.com This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested Parabilis saw its shares rise by more than SpaceX's shares did after its IPO. That doesn't mean it's guaranteed to succeed.
fool.com Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy? Director Alan Sebulsky acquired 17,500 shares for $474,000, based on a weighted average purchase price of $27.06 per share. This activity increased his ownership to 30,000 shares, held through an…
globenewswire.com Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines…